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were matched from each cohort. The bipolar cohort had higher percentages of inpa-
tient stays (18.72% vs. 2.56%, p< 0.0001) and emergency room (ER) (22.51% vs. 7.82%, 
p< 0.0001), physician office (99.40% vs. 55.89%, p< 0.0001), outpatient (99.55% vs. 
56.73%, p< 0.0001) and pharmacy visits (91.83% vs. 54.65%, p< 0.0001). Bipolar disorder 
patients also incurred higher inpatient ($6,126 vs. $775, p< 0.0001), ER visit ($265 vs. 
$72, p< 0.0001), physician office visit ($4,149 vs. $1,365, p< 0.0001), outpatient visit 
($4,566 vs. $1,538), pharmacy ($952 vs. $414, p< 0.0001) and total costs ($11,645 vs. 
$2,728, p< 0.0001) compared to patients without the disorder. ConClusions: In this 
study, bipolar disorder was associated with higher health care resource utilization 
and a significantly higher economic burden.
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objeCtives: The purpose of this study was to describe the resource use before, and 
after, initiation of long-acting injectable antipsychotics (LAI-AP) using the provincial 
public drug reimbursement program database of the Régie de l’assurance maladie du 
Québec (RAMQ). Methods: Patients who were incident users (no use in the previous 
12 months) of a LAI-AP prescribed between January 1st 2008 and March 31st 2012, 
at least 20 years old, with a diagnosis of schizophrenia/schizoaffective disorder 
and with continuous enrollment during the study period were selected. Resource 
utilization and associated costs were analyzed both during the year before LAI-AP 
initiation (pre-initiation period) and the year after (post-initiation period). Results: 
A total of 1,992 patients met the inclusion criteria. The average age was 43.5 years 
(SD= 14.3). In pre-initiation period, 1,484 patients had at least one hospitalization, 
compared to 958 in post-initiation period (p< 0.001), and the number of days hospi-
talized was reduced by half (40.5 days [SD= 39.6] vs. 21.2 days [SD= 29.9]; p< 0.001). 
The number of patients having at least one emergency room visit decreased from 
1,372 to 813 patients (p< 0.001), but the number of patients with at least one outpa-
tient clinic visit increased from 1,572 to 1,726 patients (p< 0.001). The pre-initiation 
inpatient costs were CDN$21,312 (SD= 27,303), compared to CDN$7,199 (SD= 16,419) 
in post-initiation period (p< 0.001). The outpatient costs were CDN$1,209 (SD= 1,173) 
during the pre-initiation period, and CDN$1,296 (SD= 1,284) in the post-initiation 
period (p= 0.002), while cost of medication were CDN$1,861 (SD= 2,515) vs. CDN$4,595 
(SD= 3,910) (p< 0.001). Total cost of health care resource, including LAI-AP, were 
CDN$24,382 (SD= 27,234) in the pre-initiation period, compared to CDN$13,090 
(SD= 16,987) in the post-initiation period (p< 0.001). ConClusions: The initiation 
of LAI-AP resulted in significantly lower health care resource and cost reduction, 
with the primary driver being a reduction in number of hospitalizations, days of 
hospitalization and visits to the emergency room.
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objeCtives: Even with increasing attention given to post-traumatic stress disor-
der (PTSD), limited data exist documenting PTSD-related economic burden. This 
study documents annual rates of PTSD-related hospitalizations in the US (2000-
2010), along with associated costs and length of stay [LOS]. Methods: Adult (18+ 
years old) PTSD-related hospitalizations (those with an ICD-9-CM diagnosis code 
of 309.81 [primary or secondary]) from the 2000 through 2010 HCUP Nationwide 
Inpatient Samples (NIS) were analyzed. Annual rates of PTSD hospitalization per 
100,000 adults (adjusted to 2010 US population) were estimated using NIS sampling 
weights and US Census population denominators. Additionally, cost (in 2013 $) and 
LOS estimates were calculated. Results: Rates of hospitalizations with a primary 
diagnosis of PTSD have increased over time, from 2.5/100,000 adults (5,139 hospi-
talizations) in 2000 to 4.1/100,000 (9,175 hospitalizations) in 2010, a 61.6% increase, 
and by over 200% for hospitalizations with any diagnosis of PTSD, from 28.6/100,000 
to 87.7/100,000. For hospitalizations with PTSD as the primary diagnosis, the mean 
(standard deviation [SD]) LOS increased slightly, from 5.7 (7.6) days in 2000 to 6.0 
(6.9) days in 2010, while mean (SD) costs increased by 23.2%, from $5,138 ($6,440) 
in 2000 to $6,330 ($7,281) in 2010. Finally, from 2000 to 2010, the estimated total 
(aggregate) cost of PTSD-related hospitalizations increased by 129% ($26.3 million 
to $60.3 million) for primary PTSD diagnosis hospitalizations and 471% ($435 million 
to $2.49 billion) for any PTSD diagnosis. ConClusions: PTSD-related hospitaliza-
tion rates in the US have increased during the first decade of the 2000s, with the 
total inpatient cost burden increasing at an even greater rate. Further research to 
better understand factors which may be influencing the observed growth in rates of 
PTSD-related hospitalization in the US (e.g., changing diagnostic criteria; increasing 
numbers of servicemen and women returning from military combat settings, which 
is an established PTSD risk factor) is warranted.
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objeCtives: Buprenorphine/naloxone (BUP/NAL) combination is a treatment for 
the opioid dependence. Earlier studies showed that some patients, here, alternated 
between periods on and off treatment. The aim of this study was to compare health 
care resource utilization and costs between these patients and patients treated 
continuously. Methods: Statistical analyses were conducted on a Medicaid insur-
disorders (26.5% vs. 13.6%; p< 0.001). In the follow-up period, high-cost patients 
continued to have higher rates of non-opioid substance abuse diagnoses (53.0% 
vs. 47.2%; p< 0.001) and psychotic disorders (67.1% vs. 47.5%; p< 0.001). The mean 
follow-up period health care costs of high-cost patients was $89,177 (vs. $11,653 
for low-cost patients (p< 0.001)), of which 38.8% was attributed to inpatient, 21.9% 
to outpatient, 18.6% to emergency department , 4.9% to rehabilitation facility, and 
11.0% to prescription drugs costs. ConClusions: High-cost patients diagnosed 
with opioid abuse are complicated patients with high rates of pre-existing and 
concurrent chronic comorbidities and mental health conditions.
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objeCtives: In the US, over 5 million people suffer from Alzheimer’s Disease (AD). 
The objective of this study is to estimate direct medical costs attributable to AD for 
Medicare enrollees in 2008 and 2010 according to cost category. Methods: Data 
were from the Centers for Medicare & Medicaid Services (CMS) chronic conditions 
public use files in which each record is a profile defined by all combinations of age 
category, gender, chronic conditions, and dual-eligibility status. For each profile, cost 
measures generated from claims data are provided in the form of averages by cost 
category. Our study population (n= 23.7m) included Medicare enrollees in years 2008 
and 2010 who: 1) had 12 months enrollment; 2) did not have dual eligibility; 3) were 
age 65 and over. We examined costs of hospital admissions, skilled nursing facility, 
physician and other provider visits, outpatient visits, and prescriptions medica-
tions. To determine the cost associated with AD, we estimated multivariable OLS 
linear regression models with cost as the dependent variable and a dichotomous 
AD indicator as the primary independent variable, adjusted for age, gender and 
other chronic conditions and weighted using frequency counts. Results: Adjusted 
costs associated with AD were highest for skilled nursing facility use, medications, 
and inpatient services, at $1680, $1280 and $1114, respectively, in 2010. Of the 11 
chronic conditions examined, AD was the most costly in terms of added medication 
expenditures, with added annual costs $300 more than the next closest condition, 
chronic obstructive pulmonary disorder (COPD, Table). It was also the second most 
costly condition in terms of skilled nursing facility costs, surpassed only by stroke in 
adjusted analyses. ConClusions: Interventions, including treatment for reversible 
causes, lifestyle modification, and use of cost-effective treatments, may be needed 
to stem cost increases attributable to AD, particularly as the population ages.
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objeCtives: Schizophrenia is a mental disease of chronic nature that may often 
require long time hospitalizations to be controlled. One of the major issues in con-
trolling Sc is adherence to treatment. Long-term release paliperidone palmitate 
administered intramuscularly once a month improved treatment compliance and 
diminished hospitalization rates. Our goal was to estimate the costs of hospitaliza-
tion for schizophrenic patients in Brazil (private setting) and to calculate the mon-
etary impact of adopting LRPP in an outpatient scenario. Methods: We searched a 
database of claims of five health plans in order to identify patients with schizophre-
nia. Then, we retrieved all hospitals bills for each patient and determined the final 
cost of admissions. Only direct costs were considered: medication, medical visits, 
ancillary fees, etc. To project the impact of the adoption of LRPP, we estimated that 
hospitalization rates would be reduced by 31.5% for patients admitted for less than 
one year and 35.9% for those hospitalized for up to two years, according to data from 
randomized trials. Results: We identified 18 admissions due to schizophrenia. 
Patients had a mean age of 43.4 years. Mean length of hospitalization was 126.4 days, 
corresponding to a total of 2275 days for all patients. Total hospitalization cost was 
R$ 604 889 (US$ 252 037), mean of R$ 33 604 (US$ 14 000) per hospitalization. If LRPP 
was adopted, the cost to treat these patients would be cut down to R$ 130 974 (US$ 
54 572), a reduction of 21,65%. ConClusions: Based on real world data, Sc hospi-
talization costs may be reduced by 21% if outpatient treatment with LRPP is adopted.
PMH39
exaMining tHe buRden of illness of united states veteRan Patients 
diagnosed witH biPolaR disoRdeR
Baser O.1, Wang L.2, Huang A.2, Wang Y.3, Kariburyo M.F.3, Xie L.3
1STATinMED Research and The University of Michigan, Ann Arbor, MI, USA, 2STATinMED 
Research, Dallas, TX, USA, 3STATinMED Research, Ann Arbor, MI, USA
objeCtives: To examine the economic burden and health care utilizations of bipo-
lar disorder patients in the U.S. veteran population. Methods: A retrospective data-
base analysis was performed using the Veterans Health Administration Medical SAS 
datasets from October 1, 2007 through September 30, 2012. Adult patients diagnosed 
with bipolar disorder were identified using International Classification of Disease, 
9th Revision, Clinical Modification (ICD-9-CM) diagnosis codes 296.0x, 296.1x, 296.4x, 
296.5x, 296.6x, 296.7x and 296.8x. The first diagnosis date was defined as the index 
date for the bipolar disorder cohort. A comparator cohort of patients without a 
bipolar disorder diagnosis was created using 1:1 propensity score matching to adjust 
for demographic characteristics and baseline Charlson Comorbidity Index scores. 
The index date for the comparator cohort was randomly chosen to reduce selec-
tion bias. One-year continuous enrollment was required before and after the index 
date for both cohorts. Study outcomes, including health care costs and utilizations, 
were compared between the disease and comparator cohorts. Results: After 1:1 
matching, a total of 187,530 patients with proportionate baseline characteristics 
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objeCtives: Bipolar disorder imposes high economic burden, with direct costs 
estimated at $30.7 billion. Lurasidone is an atypical antipsychotic approved for the 
treatment of depressive episodes associated with bipolar I disorder. The objective of 
this study was to compare the cost-effectiveness of lurasidone and quetiapine XR in 
patients with bipolar depression. Methods: A cost-effectiveness model was devel-
oped to compare lurasidone to quetiapine XR over a 3-month time horizon from a 
US payer perspective. Effectiveness inputs were based on indirect comparison of 
the proportion of patients achieving remission (MADRS total score ≤ 12 by week 6-8), 
obtained from lurasidone and quetiapine XR pivotal trials versus placebo. Resource 
utilization (emergency room visits, hospitalizations, and office visits) were obtained 
from an expert panel study. Drug costs were estimated using mean dose from clini-
cal trials and wholesale acquisition costs. Costs of resources were obtained from 
a retrospective database study of bipolar depression patients. Model results were 
tested using deterministic and probabilistic sensitivity analyses. Results: Over the 
3-month time horizon of the model, 52.0% of lurasidone patients achieved remission 
versus 43.2% of quetiapine XR patients. Mean emergency room visits, inpatient days, 
and office visits were lower for lurasidone patients (0.48, 2.1, 9.3) than quetiapine XR 
patients (0.50, 2.2, 9.6), respectively. Total costs were lower for lurasidone patients 
($4,447) than quetiapine XR patients ($4,546). Cost-effectiveness results showed 
that lurasidone was dominant over quetiapine XR. Model testing showed that the 
results were robust to changes in other parameters. One-way sensitivity analysis 
showed that the model may be sensitive to the drug cost/month, remission rate, or 
hospital cost/day. Probabilistic sensitivity analyses showed lurasidone has a 97.4% 
probability of being cost-effective compared to quetiapine XR at a willingness-to-pay 
threshold of $5,000 per remission. ConClusions: Based on this model, lurasidone 
is cost-effective compared to quetiapine XR in patients with bipolar depression.
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objeCtives: Generalized Anxiety Disorder (GAD) affects around 6.8 million U.S. 
adults. It places a considerable economic burden upon patients and payers alike. 
Selective serotonin reuptake inhibitors (SSRIs) are among the first-line therapy for 
treating GAD. Currently, Escitalopram and Paroxetine are the only SSRIs approved 
by U.S. FDA for treating GAD. To assess, from a third party payer’s perspective, the 
cost-effectiveness of Escitalopram and Paroxetine in the treatment of GAD in the 
U.S. Methods: A decision analytic model with a 12 month time horizon, adapted 
to the U.S. setting was constructed. Outcome measured as a reduction in Hamilton 
Anxiety Scale (HAMA) scores, and adverse event probabilities were obtained from a 
head-to-head randomized trial. Resource utilization and associated costs were esti-
mated from standard national sources. Analyses from a third party payer’s perspec-
tive focused on the direct medical cost of treatment e.g. drugs, physician visits and 
dispensing cost. Annual cost per person for the treatment was calculated and the cost-
effectiveness of the treatment options was measured. All costs were reported in 2013 
US Dollars. Cost-effectiveness was expressed as the incremental cost-effectiveness 
ratio (ICER). Sensitivity analysis on key input parameters and Monte Carlo simula-
tion was performed to measure the robustness of the model. Results: Escitalopram 
dominated Paroxetine by having both, lower total annual cost ($4587 vs. $5243, respec-
tively) and better outcomes (14 HAMA vs. 13 HAMA point reduction, respectively).The 
ICER was found to be -$656/HAMA point which indicates improved effectiveness along 
with reduction in costs by adopting Escitalopram over Paroxetine. Sensitivity analysis 
demonstrated the robustness of the model. ConClusions: Escitalopram appears 
to be cost-effective compared with Paroxetine in treatment of GAD in the U.S. from 
a third party payer’s perspective.
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objeCtives: The objectives of this study are: (1) to estimate the expected health 
outcomes of atypical antipsychotics (AAPs) and other non-stimulant attention-def-
icit/hyperactivity disorder (ADHD) medications based on trade-offs between clinical 
effectiveness and adverse effects and (2) to evaluate the cost-effectiveness of AAPs 
compared to other non-stimulant ADHD medications. Both aims target children 
and adolescents with ADHD who have failed prior stimulant therapy. Methods: 
We used decision analysis to compare three alternatives for treating children and 
adolescents with ADHD who failed initial stimulant treatment: (1) AAPs (2) a selec-
tive norepinephrine reuptake inhibitor (atomoxetine), and (3) selective a2-adrenergic 
agonists (clonidine and guanfacine). Probability estimates and quality adjusted life 
year (QALY) weights were derived from a literature review. One-way deterministic 
sensitivity analyses were performed to evaluate the robustness of the results. Cost-
effectiveness was estimated using the expected health outcomes derived from the 
decision analysis and expected costs from the literature. A Monte Carlo simulation 
was performed as a probabilistic sensitivity analysis. Results: After one year of 
ADHD pharmacotherapy, clonidine/guanfacine provided the highest expected QALY 
(0.95) followed by atomoxetine (expected QALY 0.94). Atypical antipsychotics yielded 
the lowest health outcome with an expected QALY of 0.84. In the cost-effectiveness 
analysis, the AAP strategy was dominated as it was less effective and more costly 
ance claims database (TruvenHealth MarketScan® Medicaid) from January 2007 
to June 2012. Patients with at least two treatment episodes in the first year after 
the initial filled prescription were identified. The end of a treatment episode was 
defined as a period of 60 days with no filled BUP/NAL prescriptions following 
the theoretical end of the last filled prescription. An ordered logistic regression 
model was used to analyze the impact of initial treatment episode duration on the 
number of new episodes in the year following the end of the first episode. Health 
care resource utilization and related costs during the first year after initiation 
were compared between the two groups. Results: 2,223 patients were included 
in the analysis. During the first year, 86% of patients had only one treatment 
episode, 13% had two and 1% had three. Compared to patients treated continu-
ously over 12 months, the multiple treatment episode groups had lower medica-
tion costs (-$2,877) but higher psychiatric inpatient costs (+$720), non-psychiatric 
inpatient costs (+$2001) and emergency room costs over 12 months. Total health 
care costs over 12 months were higher among multiple treatment episode patients 
($16,583 vs. $15.123, p= 0.0004). ConClusions: Despite lower medication costs, 
total health care costs over 12 months were higher among patients with multiple 
treatment episodes compared to patients treated continuously.
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objeCtives: Preliminary data from a multicenter, open-label mirror study of 
patients with schizophrenia aged 18–65 years (Kane et al. J Med Econ. 2013;16:917) 
demonstrated that switching from oral standard of care (SOC) antipsychotics 
to aripiprazole once-monthly (AOM) reduced total psychiatric hospitalization 
rates from 41.5% in the SOC 6-month retrospective period to 14.2% in the AOM 
6-month prospective period (p< 0.0001). A subgroup of patients with at least 1 
psychiatric hospitalization while receiving oral SOC in the retrospective period 
was analyzed to estimate health care cost savings associated with AOM treatment 
initiation. Methods: An economic model was developed to examine the impact 
on costs and outcomes of switching to AOM. Cost for hospitalizations, hospi-
tal length of stay, and cost of drug therapy were estimated for a subgroup of 76 
patients with schizophrenia who entered the ongoing mirror study (NCT01432444) 
and had at least 1 psychiatric hospitalization during the retrospective period. 
Cost estimates were obtained from HealthCare Costs and Utilization Project, pub-
lished literature, and US Bureau of Labor Statistics. Adjustments were made to 
estimate additional resource use for patients who discontinued the study (lost to 
follow-up, adverse events, met protocol/investigator withdrawal criteria, protocol 
deviation, lack of efficacy) and thus did not have complete data on resource use 
from the trial. Results: Among the 76 patients with hospitalizations during the 
retrospective period, hospitalizations were reduced to 22.4% (17/76, p< 0.0001) in 
the prospective AOM period. Total cost during the prospective period ($23,313) 
after switching to AOM was lower than that in the retrospective period ($36,415) 
by $13,102 per patient. Hospitalizations per patient were reduced from 1.16 to 
0.53. Increased cost due to AOM initiation ($6,010) was offset by reduced cost 
for hospitalizations (–$19,112). ConClusions: Among patients with previous 
psychiatric hospitalizations, treatment with AOM may reduce total cost of care 
for health plans.
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objeCtives: Management of patients with chronic relapsing schizophrenia is dif-
ficult and costly. We assessed the cost-effectiveness of paliperidone palmitate long-
acting injectable (PP-LAI) versus risperidone depot (RIS-LAI), olanzapine pamoate 
(OLZ-LAI), oral olanzapine (oral-OLZ) and oral clozapine (CLOZ) from the viewpoint 
of the Finnish National Health Service. Methods: We expanded and adapted a 
1-year decision tree model that had been previously validated for Finland, with 
assistance from an expert panel. Patients started in a stable state and were treated 
as per standard procedures in Finland. Drug doses, success and relapse rates were 
determined from published clinical studies. Patient management was guided by 
expert opinion. Health state utilities were derived from the literature. Only direct 
costs were considered, including hospitalization and other institutional care, medi-
cal and nursing care, and drugs. Prices were obtained from standard lists. Outcomes 
included quality-adjusted life-years (QALYs), rates of rehospitalization and days 
with stable disease. The primary economic outcome was the incremental cost/QALY. 
One-way sensitivity analyses were performed on all pertinent costs and clinical 
inputs. Results between drugs were tested in a pairwise fashion with 10,000 Monte 
Carlo simulations each, using standard distributions for all variables. Results: 
Expected costs were € 10,691 for PP-LAI, € 12,462 for RIS-LAI, € 12,496 for OLZ-LAI, 
€ 27,270 for oral-OLZ and € 23,258 for CLOZ. QALYs were 0.829, 0.813, 0.821, 0.739 
and 0.523, respectively. Rehospitalizations were 0.25, 0.30, 0.29, 0.61, and 1.88, 
respectively and days with stable disease were 329.3, 326.2, 325.1, 283.9 and 215.6, 
respectively. In the base-case, PP-LAI dominated all other drug choices. One-way 
sensitivity analyses indicated that results were insensitive to drug costs but sensi-
tive to plausible changes in rates of adherence or hospitalization. In probability 
sensitivity analyses, results were robust overall with ICERs significantly favouring 
PP-LAI (P< 0.001). ConClusions: PP-LAI was cost-effective in Finland for chronic 
relapsing schizophrenia.
